Skip to main content

Advertisement

SpringerLink
Log in

Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus

  • Original Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Objective

Using a single-center cohort of Japanese patients with SLE, we attempted to clarify the long-term outcome and factors associated with damage accrual using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).

Methods

We examined a cohort of 557 patients who had been referred to Niigata University Hospital and diagnosed as having SLE between 1961 and 2013. The patients’ data at the latest visit were collected from their clinical records, and causes of death were defined on the basis of those data. Survival from the time of diagnosis was calculated by the Kaplan–Meier method. The SDI was calculated and analyzed using Spearman’s correlation coefficient and stepwise multiple regression analysis to reveal the factors associated with any organ damage.

Results

Data from 458 of the patients were successfully obtained. The overall 5-year survival rate was 92.2%, and patients diagnosed after 2000 had a significantly high 5-year survival rate of 96.4%. Stepwise multiple regression analysis selected serum creatinine levels (B = 0.6051, p < 0.0001), age (standardized beta = 0.2762, p < 0.001), hypertension (standardized beta = 0.2267, p < 0.001), and antiphospholipid antibody syndrome (standardized beta = 0.1533, p = 0.005) as positive independent variables, whereas administration of bisphosphonate (standardized beta = − 0.1295, p = 0.016) was selected as a negative independent variable.

Conclusion

These results suggest that Japanese patients with SLE have a favorable long-term prognosis, and also indicate that disease control as well as management of chronic complications such as hypertension and osteoporosis has possible effects for prevention of organ damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Med (Baltim). 2006;85:147–56.

    Article  Google Scholar 

  2. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.

    Article  PubMed  CAS  Google Scholar 

  3. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40:809–13.

    Article  PubMed  CAS  Google Scholar 

  4. Sutton EJ, Davidson JE, Bruce IN. The Systemic Lupus International Collaborating Clinics (SLICC) Damage Index: a systematic literature review. Semin Arthritis Rheum. 2013;43:352–61.

    Article  PubMed  Google Scholar 

  5. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus. The Hopkins Lupus Cohort. Arthritis Rheum. 2012;64:4021–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Bruce IN, O’Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Linics (SLICC) inception cohort. Ann Rheum Dis. 2015;74:1706–13.

    Article  PubMed  CAS  Google Scholar 

  7. Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology. 2015;54:836–43.

    Article  PubMed  CAS  Google Scholar 

  8. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006;33:1570–7.

    PubMed  Google Scholar 

  9. Stoll T, SutcliffeN Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus- a 5-yr prospective study. Rheumatology. 2004;43:1039–44.

    Article  PubMed  CAS  Google Scholar 

  10. Sato H, Miida T, Wada Y, et al. Atherosclerosis is accelerated in patients with long-term well-controlled systemic lupus erythematosus (SLE). Clin Chim Acta. 2007;385:35–42.

    Article  PubMed  CAS  Google Scholar 

  11. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex, and disease duration in systemic lupus erythematosus. Rheumatol (Oxf). 2003;42:276–9.

    Article  CAS  Google Scholar 

  12. Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Duran S, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINALV). Ann Rheum Dis. 2007;66:618–22.

    Article  PubMed  Google Scholar 

  13. Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56:2092–4.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Cooper GS, Parks CG, Treadwell EL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the Southeastern United States. Lupus. 2002;11:161–7.

    Article  PubMed  CAS  Google Scholar 

  15. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039–46.

    Article  PubMed  Google Scholar 

  16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.

    Article  PubMed  CAS  Google Scholar 

  17. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.

    Article  PubMed  CAS  Google Scholar 

  18. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309–11.

    Article  PubMed  CAS  Google Scholar 

  19. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.

    Article  PubMed  CAS  Google Scholar 

  20. Ugarte-Gil MF, Pons-Estel GJ, Molineros J, Wojdyla D, McGwin G, Nath SK, et al. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology. 2016;55:436–40.

    PubMed  Google Scholar 

  21. Gomez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcon GS, Costenbader KH. Racial/ethnic variation in all-cause mortality among United States Medicaid recipients with systemic lupus erythematosus. a Hispanic and Asian paradox. Arthritis Rheum. 2015;67:752–60.

    Article  Google Scholar 

  22. Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337–50.

    Article  PubMed  Google Scholar 

  23. Themaer M, Hernan MA, Zhang Y, Cotter D, Petri M. Relationship between prednisolone, Lupus activity and permanent organ damage. J Rheumatol. 2009;36:560–4.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Professor Naohito Tanabe, University of Niigata Prefecture, for his kind advice regarding statistical analyses in this study.

Author information

Authors and Affiliations

  1. Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-Dori, Chuo-ku, Niigata, 951-8510, Japan

    Yoko Wada & Ichiei Narita

  2. Division of Clinical Nephrology and Rheumatology, Niigata City General Hospital, Niigata, Japan

    Hisashi Hasegawa

  3. Division of Clinical Nephrology and Rheumatology, Nagaoka Red Cross Hospital, Nagaoka, Japan

    Takako Saeki

  4. Division of Rheumatology, Niigata Prefectural Rheumatic Center, Shibata, Japan

    Satoshi Ito

  5. Health Administration Office, Niigata University, Niigata, Japan

    Takeshi Kuroda

  6. School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan

    Masaaki Nakano

Authors
  1. Yoko Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisashi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takako Saeki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Satoshi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeshi Kuroda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masaaki Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ichiei Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoko Wada.

Ethics declarations

Conflict of interest

All authors do not have any conflict of interest regarding to the study.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 1754) and with the Declaration of Helsinki and the ethical guidelines for epidemiological studies issued by the Ministry of Health, Labour and Welfare of Japan.

Informed consent

Because data were retrospectively obtained from medical records, informed consent was not obtained in accordance with the above ethical guidelines.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wada, Y., Hasegawa, H., Saeki, T. et al. Long-term prognosis and factors associated with damage accrual in Japanese patients with systemic lupus erythematosus. Clin Exp Nephrol 22, 597–602 (2018). https://doi.org/10.1007/s10157-017-1491-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-017-1491-9

Keywords

Search

Navigation